Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) has announced its participation in the upcoming Stifel Healthcare Conference. The company's management will engage in a fireside chat on Monday, Nov. 18, 2024, at 11:30 a.m. ET. Acumen, a clinical-stage biopharmaceutical company, is developing a novel treatment targeting toxic soluble amyloid beta oligomers for Alzheimer's disease. The presentation will be accessible via live webcast on the company's website under the Investors tab and will remain available for 90 days following the event.

News Market Reaction – ABOS

-16.93%

-16.93% Session move

In the trading session that priced this news, ABOS declined 16.93%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. 

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When is Acumen Pharmaceuticals (ABOS) presenting at the Stifel Healthcare Conference 2024?

Acumen Pharmaceuticals will present at the Stifel Healthcare Conference on Monday, November 18, 2024, at 11:30 a.m. ET.

How can I watch Acumen Pharmaceuticals' (ABOS) Stifel Healthcare Conference presentation?

The presentation can be accessed via live webcast under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

What type of treatment is Acumen Pharmaceuticals (ABOS) developing?

Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

What format will Acumen Pharmaceuticals' (ABOS) presentation take at the Stifel Conference?

The presentation will be in the format of a fireside chat at the Stifel Healthcare Conference.